Detection minimal residual disease T-cell acute lymphoblastic leukemia polymerase chain reaction relapse remission one-third patients T-cell acute lymphoblastic leukemia T-ALL relapse due resurgence residual leukemic cells remission morphologic methods early detection residual disease desirable efficacy therapy alternative mode therapy aim applicability polymerase chain reaction PCR amplification detection minimal residual disease MRD bone marrow samples patients T-ALL morphologic remission different approaches leukemic clone-specific sequences targets PCR amplification first technique T-cell receptor-delta TCR-delta gene rearrangements PCR amplification leukemic DNA method successful clone-specific probes T-ALL patients alternative method TCR-beta chain gene leukemic cells specific probe PCR specific patient leukemic clone capable leukemic cell normal cells sensitive PCR-based assays evidence persistence leukemic clone bone marrow samples T-ALL patients long-term years remission contrast residual disease clinical remission samples patients patient appropriate samples dramatic expansion leukemic clone months clinical relapse results PCR-based assays detection MRD T-ALL patients great potential relapse efficacy anti-leukemic therapy methods identification long-term survivors 